ARROWHEAD PHARMACEUTICALS IN
ARWRNASDAQ🏆 #612 by market capUS Equity
$828.49▲ $22.12 (+2.67%)
Simulated price1h—
24h▲ 2.7%
7d▲ 853.8%
14d▲ 861.1%
30d▲ 1017.5%
1y▲ 4555.7%
🏦Market Cap
$12.48B
Mid Cap
📈Revenue Growth (YoY)
+16.9%
Healthy
📊Gross Margin
—
💵FCF Margin
15.9%
Healthy
⚖️P/S Ratio
18.6x
Expensive
Otter Score
59
Weak
Trading Snapshot
- Day Range
- $818.03 – $834.17
- 52-Week Range
- $15.01 – $95.49
- Volume
- $4.11B
- Avg Volume
- $5.09B
- Shares Outstanding
- 140.9M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $670M
- Last Q Revenue
- $180M
- P/E Ratio
- —
- P/S Ratio
- 18.6x
- EPS (TTM)
- $-2.24
- Dividend Yield
- —
Why Investors Own ARWR
- ✓High-growth profile — revenue up +12.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$670M▲ +10.3% YoY
Gross Margin (TTM)
25.6%▲ +4.1% YoY
Operating Income (TTM)
$145M▲ +10.3% YoY
Free Cash Flow (TTM)
$63M▲ +10.3% YoY
About ARROWHEAD PHARMACEUTICALS IN
A company profile for ARROWHEAD PHARMACEUTICALS IN isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
59/100
Analyst Price Target
ⓘAverage Target
$834.85
▲ +0.8% Upside
High Target$927.39
Low Target$639.94
Based on 18 analysts
Latest News & Updates
🚀
CNBC·2h ago
ARROWHEAD PHARMACEUTICALS IN tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift ARWR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
ARROWHEAD PHARMACEUTICALS IN announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.